Altamira Therapeutics shares are trading higher after highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media channels of the journal, "Allergy."
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics shares are trading higher following the publication of highlights from its NASAR clinical trial with Bentrio nasal spray on the social media channels of the journal, 'Allergy.'
May 23, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altamira Therapeutics shares are experiencing an upward trend after the NASAR clinical trial highlights for its Bentrio nasal spray were shared on the social media channels of the journal, 'Allergy.'
The publication of clinical trial highlights on a reputable journal's social media channels can increase visibility and credibility, likely driving investor interest and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100